Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

OPK

Opko Health Inc

Oct 31 • 04:00PM ET

1.36

-0.10 -6.85 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: LH DGX MYGN EXAS MEDP CMRX VNDA BCRX TECH CRL

| Held by: VTI IWM VB VXF IWN VBR VBK SCHA IBB VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.25	Insider Own	48.95%	Shs Outstand	768.70M	Perf Week	-9.33%
Market Cap	1.04B	Forward P/E	-	EPS next Y	-0.26	Insider Trans	0.20%	Shs Float	391.88M	Perf Month	-11.69%
Enterprise Value	1.02B	PEG	-	EPS next Q	-0.06	Inst Own	28.89%	Short Float	8.52%	Perf Quarter	7.09%
Income	-180.42M	P/S	1.63	EPS this Y	-310.00%	Inst Trans	-8.24%	Short Ratio	14.47	Perf Half Y	-1.81%
Sales	642.03M	P/B	0.80	EPS next Y	22.26%	ROA	-8.49%	Short Interest	33.37M	Perf YTD	-7.48%
Book/sh	1.70	P/C	2.51	EPS next 5Y	-2.04%	ROE	-13.32%	52W High	2.04 -33.17%	Perf Year	-15.00%
Cash/sh	0.54	P/FCF	-	EPS past 3/5Y	-18.15% 32.04%	ROIC	-10.76%	52W Low	1.11 22.52%	Perf 3Y	-28.04%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-26.21% -4.59%	Gross Margin	22.96%	Volatility	5.14% 3.53%	Perf 5Y	-68.45%
Dividend TTM	-	EV/Sales	1.60	EPS Y/Y TTM	-31.28%	Oper. Margin	-33.30%	ATR (14)	0.06	Perf 10Y	-86.60%
Dividend Ex-Date	-	Quick Ratio	3.32	Sales Y/Y TTM	-9.75%	Profit Margin	-28.10%	RSI (14)	34.66	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	3.70	EPS Q/Q	11.24%	SMA20	-9.30%	Beta	1.50	Target Price	3.56
Payout	-	Debt/Eq	0.30	Sales Q/Q	-12.65%	SMA50	-6.81%	Rel Volume	1.70	Prev Close	1.46
Employees	2997	LT Debt/Eq	0.28	Earnings	Oct 29 AMC	SMA200	-7.10%	Avg Volume	2.31M	Price	1.36
IPO	Nov 02, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	145.05% -5.65%	Trades		Volume	3,912,191	Change	-6.85%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Downgrade	Jefferies	Buy → Hold	$1.60
Apr-25-25	Initiated	JP Morgan	Neutral
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform	$2
Dec-15-22	Initiated	H.C. Wainwright	Buy	$3
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy	$7
Nov-25-19	Initiated	Piper Jaffray	Overweight	$2.50
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy	$16 → $18
Jun-03-16	Initiated	Standpoint Research	Buy	$16
Mar-31-16	Reiterated	Barrington Research	Outperform	$17 → $16
Oct-16-15	Initiated	JP Morgan	Overweight	$14
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform	$13 → $12
Mar-14-14	Initiated	Oppenheimer	Outperform	$13
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy	$10 → $14.50
May-30-13	Reiterated	Ladenburg Thalmann	Buy	$8.50 → $10
Oct-22-12	Initiated	Barrington Research	Outperform	$6

Show Previous Ratings

Oct-30-25 11:29PM	Opko Health Inc.'s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals (Insider Monkey) -6.85%
12:24PM	OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands (Zacks)
Oct-29-25 06:30PM	Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics (Zacks)
05:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
04:42PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications (GlobeNewswire)
Oct-28-25 08:00AM	OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers (GlobeNewswire)
Oct-23-25 01:56PM	Here's Why You Should Add OPKO Health Stock to Your Portfolio (Zacks)
Oct-22-25 04:05PM	OPKO Health to Report Third Quarter 2025 Financial Results on October 29 (GlobeNewswire)
Oct-01-25 01:44PM	OPKO Health, Inc. (OPK)'s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1 (Insider Monkey)
Sep-17-25 08:52AM	LH Stock Rises on Acquisition of BioReference Health's Select Assets (Zacks)
Sep-15-25 08:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Sep-11-25 12:20PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Aug-17-25 06:23PM	OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics (Insider Monkey)
04:05PM	Loading…
Aug-08-25 04:05PM	Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-06-25 03:27PM	RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment. (Barrons.com)
Aug-04-25 10:01AM	Opko Health (OPK) Reports Fiscal Q2 2025 Results (Insider Monkey) +6.72%
Aug-01-25 12:20PM	OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands (Zacks) -7.03%
06:47AM	OPKO Health (OPK) to Present Short Bowel Syndrome Treatment in Prague (Insider Monkey)
Jul-31-25 07:00PM	Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics (Zacks)
05:45PM	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:45PM	OPKO Health: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Jul-24-25 04:05PM	OPKO Health to Report Second Quarter 2025 Financial Results on July 31 (GlobeNewswire)
Jul-23-25 11:25AM	OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) (Insider Monkey)
Jul-08-25 08:00AM	OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress (GlobeNewswire)
Jul-07-25 09:10AM	H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 (Insider Monkey)
Jun-25-25 11:00AM	OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium (GlobeNewswire)
08:00AM	OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting (GlobeNewswire)
03:52PM	Loading…
Jun-24-25 03:52PM	Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT (Insider Monkey)
Jun-13-25 12:37PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Jun-09-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development (GlobeNewswire)
May-15-25 08:00AM	OPKO Health to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-01-25 12:43PM	OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands (Zacks)
08:57AM	Q1 2025 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:17AM	OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Apr-30-25 07:52PM	OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:50PM	OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Apr-22-25 09:35AM	Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround (Zacks)
Apr-17-25 09:38AM	Labcorp Holdings: Regaining Credibility (Seeking Alpha)
08:00AM	OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 (GlobeNewswire)
Apr-11-25 04:05PM	NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program (PR Newswire)
Apr-04-25 08:00AM	OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program (GlobeNewswire)
Mar-28-25 09:35AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Mar-18-25 11:37AM	Opko and Entera focus on oral care for obesity and metabolic disorders (Pharmaceutical Technology)
Mar-17-25 08:00AM	OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (GlobeNewswire)
Mar-14-25 06:59PM	Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. (Barrons.com)
12:07PM	Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? (Insider Monkey)
Mar-12-25 12:10PM	Labcorp to acquire certain assets of Opko Healths BioReference Health (TipRanks)
11:06AM	Truist remains bullish on Labcorp after another nice strategic acquisition (TipRanks)
Mar-11-25 07:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Feb-28-25 09:01AM	Q4 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.75%
02:35AM	OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com)
Feb-27-25 10:45PM	Opko Health (OPK) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00PM	OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates (Zacks)
05:58PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:10PM	OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Feb-25-25 09:15AM	Countdown to OPKO Health (OPK) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-13-25 04:05PM	OPKO Health to Report Fourth Quarter 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Feb-12-25 09:15AM	Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
Jan-27-25 08:00AM	Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-20-25 10:02PM	OPKO Health, Inc. (OPK) Stock: An Under $5 Gem with Biggest Upside Potential (Insider Monkey)
Jan-09-25 11:45AM	OPKO Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck (GlobeNewswire)
Dec-11-24 02:08AM	Is OPKO Health (OPK) the Best NASDAQ Penny Stock to Buy Right Now? (Insider Monkey)
Dec-10-24 08:00AM	NextPlat Gains e-Commerce Access to Over 340 Million Consumers with Launch on JD.Com, China's Largest Online Retailer (PR Newswire)
Nov-29-24 02:43PM	Sleep Number, Getty Images, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-20-24 08:00AM	OPKO Health to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 08:00AM	NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo (PR Newswire)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-14-24 06:00AM	NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results (PR Newswire)
Nov-08-24 04:05PM	Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates (GlobeNewswire)
04:01AM	OPKO Health Inc (OPK) Q3 2024 Earnings Call Highlights: A Turnaround in Profitability Amidst ... (GuruFocus.com)
Nov-07-24 10:15PM	Opko Health (OPK) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About OPKO Health (OPK) Q3 Earnings (Zacks)
06:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
05:35PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	Aspira Women's Health Expands Co-Marketing and Distribution Collaboration with BioReference to Include OvaWatch (GlobeNewswire)
Oct-29-24 04:05PM	OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire) +6.67% -5.00%
Oct-07-24 08:00AM	NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan (PR Newswire)
08:00AM	ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program (GlobeNewswire)
Sep-25-24 08:30AM	Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders (GlobeNewswire)
Sep-23-24 08:00AM	OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development (GlobeNewswire)
Sep-16-24 07:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health (PR Newswire)
Aug-09-24 04:05PM	Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-08-24 12:14PM	OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down (Zacks) +11.72%
12:15AM	Opko Health (OPK) Q2 2024 Earnings Call Transcript (Motley Fool)
Aug-07-24 08:00PM	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:59PM	OPKO Health: Q2 Earnings Snapshot (Associated Press Finance)
04:06PM	OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-01-24 04:05PM	OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jul-18-24 08:00AM	OPKO Health Announces $100 Million Share Repurchase Program (GlobeNewswire) +7.04%
Jul-17-24 04:14PM	OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments (GlobeNewswire)
Jul-08-24 06:54PM	OPKO Health, Inc. (OPK): Most Shorted Stock Loved by Analysts Right Now? (Insider Monkey)

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FROST PHILLIP MD ET AL	CEO & Chairman	Oct 31 '25	Buy	1.42	150,000	213,435	214,386,448	Oct 31 05:15 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Aug 08 '25	Buy	1.32	675,000	891,000	214,676,448	Aug 08 04:56 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 10 '25	Buy	1.36	125,000	169,712	214,001,448	Apr 10 05:07 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 08 '25	Buy	1.48	125,000	184,650	213,876,448	Apr 08 05:34 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Apr 01 '25	Buy	1.65	100,000	164,850	213,751,448	Apr 01 05:21 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 28 '25	Buy	1.70	150,000	254,385	213,651,448	Mar 28 05:22 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Mar 17 '25	Buy	1.74	200,000	347,820	213,501,448	Mar 17 05:27 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Feb 28 '25	Buy	1.71	67,434	115,312	213,301,448	Feb 28 07:34 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 28 '25	Buy	1.47	47,537	70,060	213,234,014	Jan 28 05:40 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 17 '25	Buy	1.47	150,000	220,425	213,186,477	Jan 17 05:06 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Jan 15 '25	Buy	1.48	500,000	740,850	213,036,477	Jan 15 05:18 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Dec 13 '24	Buy	1.59	125,000	199,375	212,536,477	Dec 13 05:04 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Dec 11 '24	Buy	1.56	500,000	781,050	212,411,477	Dec 11 05:21 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 29 '24	Buy	1.53	199,072	305,376	211,911,477	Nov 29 03:20 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 22 '24	Buy	1.59	100,000	159,000	211,712,405	Nov 22 05:17 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 14 '24	Buy	1.62	100,000	161,980	211,612,405	Nov 14 05:51 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 08 '24	Buy	1.50	280,183	421,535	211,512,405	Nov 08 05:40 PM

Open in Screener

BCDA

BioCardia Inc

Oct 31 • 04:00PM ET

1.40

+0.14 11.11 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE NTLA CLLS QURE EDIT SGMO FATE BOLD CLRB

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-2.10	Insider Own	29.87%	Shs Outstand	10.61M	Perf Week	0.72%
Market Cap	14.86M	Forward P/E	-	EPS next Y	-1.12	Insider Trans	38.85%	Shs Float	7.44M	Perf Month	3.70%
Enterprise Value	14.62M	PEG	-	EPS next Q	-0.23	Inst Own	3.03%	Short Float	4.12%	Perf Quarter	-28.57%
Income	-8.79M	P/S	-	EPS this Y	58.10%	Inst Trans	4.14%	Short Ratio	0.41	Perf Half Y	-47.76%
Sales	0.00M	P/B	-	EPS next Y	7.41%	ROA	-353.24%	Short Interest	0.31M	Perf YTD	-35.78%
Book/sh	-0.34	P/C	15.16	EPS next 5Y	26.75%	ROE	-737.89%	52W High	3.20 -56.25%	Perf Year	-42.15%
Cash/sh	0.09	P/FCF	-	EPS past 3/5Y	36.28% 40.58%	ROIC	-	52W Low	1.00 40.00%	Perf 3Y	-95.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-61.48% -39.41%	Gross Margin	-	Volatility	8.00% 7.42%	Perf 5Y	-95.62%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	60.53%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-99.28%
Dividend Ex-Date	-	Quick Ratio	0.33	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	47.31	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.33	EPS Q/Q	53.81%	SMA20	-0.87%	Beta	0.77	Target Price	15.50
Payout	-	Debt/Eq	-	Sales Q/Q	-100.00%	SMA50	-12.57%	Rel Volume	0.27	Prev Close	1.26
Employees	20	LT Debt/Eq	-	Earnings	Aug 11 BMO	SMA200	-33.32%	Avg Volume	753.08K	Price	1.40
IPO	Nov 13, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	20.00% -	Trades		Volume	203,453	Change	11.11%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Oct-30-25 08:00AM	BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Oct-02-25 08:00AM	BioCardia Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-22-25 08:00AM	BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Sep-18-25 09:15AM	BioCardia Announces Pricing of Up To $12 Million Public Offering (GlobeNewswire) -23.78%
07:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up (GlobeNewswire)
09:00AM	Loading…
Sep-04-25 09:00AM	BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 (GlobeNewswire)
Aug-13-25 08:00AM	BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology (GlobeNewswire) +6.90%
Aug-11-25 09:15AM	BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.15%
Aug-06-25 03:18PM	BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 (GlobeNewswire) -5.52%
Aug-04-25 06:00AM	BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP Cell Therapy for Heart Failure and Helix Transendocardial Delivery Catheter (GlobeNewswire) -7.98%
Jul-24-25 09:00AM	BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP Cell Therapy in Ischemic Heart Failure (GlobeNewswire)
Jul-16-25 08:45AM	Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Jun-25-25 08:00AM	BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
May-21-25 08:30AM	BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 (GlobeNewswire)
May-15-25 03:16AM	BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... (GuruFocus.com) -16.25%
04:05PM	Loading…
May-14-25 04:05PM	BioCardia Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
May-09-25 04:28PM	BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 (GlobeNewswire)
May-06-25 08:00AM	BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
May-02-25 11:03AM	First subject enrolled in BioCardias Phase III heart failure therapy trial (Clinical Trials Arena) -5.96%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Loading…
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Nov-01-23 05:04PM	BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023 (GlobeNewswire)
Oct-12-23 11:08AM	BioCardia (BCDA) Up on Plans for Second Heart Failure Study (Zacks) -13.88%
Oct-11-23 06:00AM	BioCardia Announces Completion of Enrollment in Phase III CardiAMP HF Trial and Plans for CardiAMP HF Trial II (GlobeNewswire) +28.30%
Sep-06-23 10:31AM	BioCardia (BCDA) Dips 26% on Flunking Heart Failure Study (Zacks) -12.59%
07:15AM	BioCardia Announces Clarification and Next Steps on its Autologous CardiAMP Cell Therapy Programs (GlobeNewswire)
Sep-05-23 07:15AM	BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial (GlobeNewswire) -25.54%
Aug-11-23 09:29AM	BioCardia, Inc. (NASDAQ:BCDA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-09-23 06:05PM	BioCardia, Inc. (BCDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +6.28%
04:05PM	BioCardia Reports Second Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and Avance Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STERTZER SIMON H	Director	Sep 19 '25	Buy	1.25	398,400	498,000	591,054	Sep 23 09:00 AM
Blank Andrew Scott	Director	Sep 19 '25	Buy	1.25	288,000	360,000	634,023	Sep 23 09:00 AM
Altman Peter	President and CEO	Sep 19 '25	Buy	1.25	48,000	60,000	216,762	Sep 23 09:00 AM
Altman Peter	President and CEO	Aug 22 '25	Buy	1.83	700	1,281	168,762	Aug 25 09:30 AM
Altman Peter	President and CEO	Aug 13 '25	Buy	1.83	100	183	168,062	Aug 13 06:59 PM
Altman Peter	President and CEO	Aug 12 '25	Buy	1.75	400	700	167,962	Aug 12 07:23 PM
Altman Peter	President and CEO	Aug 11 '25	Buy	1.76	1,700	2,989	167,562	Aug 11 07:21 PM
McClung David	Chief Financial Officer	Jun 30 '25	Buy	2.08	4,819	9,999	47,950	Jul 02 09:03 PM
Altman Peter	President and CEO	Jun 30 '25	Buy	2.08	24,096	49,999	165,862	Jul 02 09:02 PM
STERTZER SIMON H	Director	Jun 30 '25	Buy	2.08	72,289	150,000	192,654	Jul 02 09:02 PM
Blank Andrew Scott	Director	Jun 30 '25	Buy	2.08	72,289	150,000	346,023	Jul 02 09:01 PM
Altman Peter	President and CEO	May 30 '25	Buy	2.21	100	221	141,766	May 30 08:55 PM
Altman Peter	President and CEO	May 20 '25	Buy	2.08	1,600	3,328	140,966	May 22 06:45 PM
Altman Peter	President and CEO	May 22 '25	Buy	1.89	700	1,323	141,666	May 22 06:45 PM
Altman Peter	President and CEO	May 16 '25	Buy	2.43	300	730	139,366	May 16 05:31 PM
Altman Peter	President and CEO	May 14 '25	Buy	2.99	100	299	139,066	May 16 05:31 PM
KRASNO RICHARD M	Director	Apr 23 '25	Buy	1.91	13,123	24,999	16,268	Apr 28 06:46 PM
McClung David	Chief Financial Officer	Apr 23 '25	Buy	1.91	13,123	24,999	43,131	Apr 25 09:38 PM
Facteau Bill	Director	Apr 23 '25	Buy	1.91	13,123	24,999	13,123	Apr 25 09:37 PM
Blank Andrew Scott	Director	Apr 23 '25	Buy	1.91	131,233	249,999	265,957	Apr 25 09:36 PM
STERTZER SIMON H	Director	Apr 23 '25	Buy	1.91	104,986	199,998	120,365	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 23 '25	Buy	1.91	26,246	49,999	138,966	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 15 '25	Buy	2.14	100	214	112,720	Apr 17 07:44 PM
Altman Peter	President and CEO	Apr 11 '25	Buy	2.03	300	609	112,620	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 10 '25	Buy	1.99	300	597	112,320	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 07 '25	Buy	1.96	500	980	112,020	Apr 08 05:01 PM
Altman Peter	President and CEO	Apr 04 '25	Buy	2.04	800	1,632	111,520	Apr 07 05:10 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.20	600	1,320	110,720	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 02 '25	Buy	2.23	500	1,115	110,120	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.24	1,200	2,688	109,620	Apr 03 09:08 PM
STERTZER SIMON H	Director	Mar 05 '25	Buy	2.45	1,000	2,450	57,138	Mar 07 08:30 AM
STERTZER SIMON H	Director	Mar 03 '25	Buy	2.30	22,753	52,332	40,602	Mar 05 08:30 AM
STERTZER SIMON H	Director	Mar 04 '25	Buy	2.30	15,536	35,733	56,138	Mar 05 08:30 AM
Altman Peter	President and CEO	Mar 03 '25	Buy	2.11	500	1,055	108,420	Mar 04 08:30 AM
Altman Peter	President and CEO	Feb 07 '25	Buy	2.48	600	1,488	107,920	Feb 11 05:42 PM
Altman Peter	President and CEO	Jan 29 '25	Buy	2.40	500	1,200	107,081	Jan 30 08:36 PM
Altman Peter	President and CEO	Jan 30 '25	Buy	2.38	239	569	107,320	Jan 30 08:36 PM
Altman Peter	President and CEO	Dec 23 '24	Buy	2.06	1,000	2,060	106,581	Dec 26 02:30 PM
GILLIS EDWARD M	Senior Vice President, Devices	Dec 20 '24	Sale	2.00	3,257	6,514	8,968	Dec 26 02:30 PM
GILLIS EDWARD M	Officer	Dec 17 '24	Proposed Sale	2.03	3,257	6,611		Dec 17 11:50 AM
Altman Peter	President and CEO	Dec 05 '24	Buy	2.22	250	555	105,581	Dec 09 05:04 PM
Altman Peter	President and CEO	Nov 15 '24	Buy	1.87	1,350	2,524	105,331	Nov 19 08:00 AM

Open in Screener

FLNT

Fluent Inc

Oct 31 • 04:00PM ET

2.13

+0.01 0.47 %

Communication Services • Advertising Agencies • USA • NASD

Peers: TTD MGNI ZS APPS PERI APP CRTO PUBM DV ACMR

| Held by: VTI VXF BSVO IWC DFSU

Index	-	P/E	-	EPS (ttm)	-1.36	Insider Own	60.30%	Shs Outstand	24.27M	Perf Week	0.47%
Market Cap	60.69M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	-0.18%	Shs Float	11.31M	Perf Month	-4.05%
Enterprise Value	80.69M	PEG	-	EPS next Q	-0.12	Inst Own	22.50%	Short Float	2.49%	Perf Quarter	-11.25%
Income	-26.87M	P/S	0.26	EPS this Y	41.23%	Inst Trans	-0.09%	Short Ratio	0.43	Perf Half Y	-12.35%
Sales	229.84M	P/B	2.70	EPS next Y	61.19%	ROA	-31.07%	Short Interest	0.28M	Perf YTD	-15.48%
Book/sh	0.79	P/C	9.20	EPS next 5Y	63.60%	ROE	-115.36%	52W High	3.46 -38.44%	Perf Year	-32.81%
Cash/sh	0.23	P/FCF	56.72	EPS past 3/5Y	-33.63% -68.62%	ROIC	-108.24%	52W Low	1.50 42.00%	Perf 3Y	-72.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.21% -2.00%	Gross Margin	18.08%	Volatility	3.19% 6.11%	Perf 5Y	-85.86%
Dividend TTM	-	EV/Sales	0.35	EPS Y/Y TTM	63.95%	Oper. Margin	-8.38%	ATR (14)	0.13	Perf 10Y	-94.76%
Dividend Ex-Date	-	Quick Ratio	0.95	Sales Y/Y TTM	-12.84%	Profit Margin	-11.69%	RSI (14)	46.96	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.95	EPS Q/Q	59.89%	SMA20	-2.96%	Beta	1.28	Target Price	3.00
Payout	-	Debt/Eq	1.39	Sales Q/Q	-23.86%	SMA50	-1.34%	Rel Volume	0.05	Prev Close	2.12
Employees	210	LT Debt/Eq	0.30	Earnings	Aug 19 AMC	SMA200	-6.41%	Avg Volume	659.06K	Price	2.13
IPO	Dec 27, 2007	Option/Short	No / Yes	EPS/Sales Surpr.	9.43% -15.16%	Trades		Volume	35,911	Change	0.47%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-22	Upgrade	Barrington Research	Mkt Perform → Outperform	$2.50
Mar-17-21	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-02-20	Upgrade	Barrington Research	Mkt Perform → Outperform	$4.50
Aug-26-20	Initiated	Canaccord Genuity	Buy	$5
Nov-12-19	Downgrade	Barrington Research	Outperform → Mkt Perform
May-09-19	Upgrade	ROTH Capital	Neutral → Buy	$5.50 → $8.50

Oct-21-25 06:20PM	Omnicom (OMC) Q3 Earnings and Revenues Beat Estimates (Zacks)
Oct-16-25 08:30AM	Rebuy Monetize Powered by Fluent Accelerates Merchant Growth as Partnership Scales Across Shopify (GlobeNewswire)
Sep-17-25 08:30AM	Fluent Named to Crain's New York Business 2025 Best Places to Work List (GlobeNewswire) -5.21%
Sep-02-25 08:30AM	Fluent, Inc. to Participate in 18th Annual Barrington Research Virtual Fall Investment Conference (GlobeNewswire) -7.98%
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +9.55%
08:30AM	Loading…
08:30AM	Fluent, Inc. Expands Data Intelligence & Data Collaboration Capabilities with Strategic Databricks Partnership and Key Leadership Hire (GlobeNewswire)
Aug-20-25 03:06AM	Fluent Inc (FLNT) Q2 2025 Earnings Call Highlights: Navigating Revenue Declines with Strategic ... (GuruFocus.com) -12.72%
Aug-19-25 06:20PM	Fluent (FLNT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Fluent: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fluent Announces Second Quarter 2025 Financial Results; Commerce Media Solutions Annual Revenue Run Rate Exceeds $80 Million (GlobeNewswire)
04:04PM	Fluent Announces $10.3 Million Private Placement of Securities (GlobeNewswire)
Aug-18-25 09:19AM	Fluent Inc (FLNT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-14-25 05:40PM	Gambling.com Group Limited (GAMB) Q2 Earnings and Revenues Beat Estimates (Zacks)
08:30AM	Fluent, Inc. Adds Authentic Brands Group to Partner Network, Powering Post-Purchase Monetization Across Brand Portfolio (GlobeNewswire)
Aug-13-25 08:30AM	Fluent, Inc. to Announce 2025 Second Quarter Financial Results and Host Earnings Conference Call on August 19, 2025 (GlobeNewswire) +7.52%
08:30AM	Loading…
Aug-11-25 08:30AM	Fluent, Inc. to Attend 45th Annual Canaccord Genuity Growth Conference (GlobeNewswire)
Aug-07-25 08:44PM	FLINT Announces Transformational Recapitalization (GlobeNewswire)
07:45AM	Teads Holding Co. (TEAD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-06-25 07:05PM	Deluxe (DLX) Q2 Earnings Beat Estimates (Zacks)
Jul-31-25 05:00PM	FLINT Announces Second Quarter 2025 Financial Results (GlobeNewswire) -8.30%
May-29-25 08:30AM	Fluent, Inc. Expands Board of Advisors, Tapping Industry Experts for Commerce Media Growth (GlobeNewswire)
May-16-25 10:03AM	Q1 2025 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
03:14AM	Fluent Inc (FLNT) Q1 2025 Earnings Call Highlights: Strategic Growth in Commerce Media Amid ... (GuruFocus.com)
May-15-25 05:55PM	Fluent (FLNT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Fluent Announces First Quarter 2025 Financial Results; Strategic Pivot Accelerates with Growth of Commerce Media Solutions (GlobeNewswire)
May-14-25 09:59AM	Fluent Inc (FLNT) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-12-25 12:00PM	Fluent, Inc. to Announce 2025 First Quarter Financial Results and Host Earnings Conference Call on May 15, 2025 (GlobeNewswire)
May-08-25 05:00PM	FLINT Announces First Quarter 2025 Financial Results (GlobeNewswire)
08:30AM	Fluent, Inc. and Rebuy Partner to Unlock Post-Purchase Advertising for Shopify Merchants (GlobeNewswire)
Apr-25-25 09:40AM	Is Fluent (FLNT) Stock Outpacing Its Business Services Peers This Year? (Zacks)
07:28AM	Loading…
Apr-23-25 07:28AM	New Strong Buy Stocks for April 23rd (Zacks) +12.90%
Apr-15-25 08:30AM	Fluent, Inc. Unveils Enhanced Identity Graph to Power Smarter Personalization and Campaign Performance (GlobeNewswire)
Mar-25-25 08:45AM	Fluent announces $5M private offering (TipRanks) +5.19%
Mar-24-25 08:30AM	Fluent, Inc. Announces $5.0 Million Private Offering (GlobeNewswire)
Mar-01-25 02:58AM	Q4 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	Fluent Inc (FLNT) Q4 2024 Earnings Call Highlights: Navigating Challenges with Commerce Media Growth (GuruFocus.com)
Feb-28-25 09:10AM	Fluent (FLNT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Fluent Announces Unaudited Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 08:00PM	Fluent, Inc. to Announce Unaudited 2024 Fourth Quarter and Full-Year Financial Results and Host Earnings Conference Call on February 28, 2025 (GlobeNewswire) +5.49%
Feb-19-25 08:30AM	Fluent, Inc. Appoints Adrian Stack as Chief Product Officer; Accelerates AI-Powered Innovation in Commerce Media (GlobeNewswire)
Feb-05-25 08:30AM	Fluent, Inc. Survey Finds That Shoppers Embrace Post-Purchase Ads, Citing Personalization & Relevance as Key Benefits (GlobeNewswire)
Jan-27-25 12:00PM	Fluent, Inc. Named to Ad Age's 2025 Best Places to Work List (GlobeNewswire)
Jan-17-25 03:34PM	Global Value Investment Corporation's Interim CEO and President JP Geygan Appointed to Fluent, Inc.'s Board of Directors (GlobeNewswire)
Jan-07-25 08:30AM	Fluent, Inc. Announces Commerce Media Partnerships with Top-Tier Brands (GlobeNewswire) +6.04%
Dec-06-24 03:17PM	Why Is Fluent, Inc. (FLNT) Among The Best Advertising Stocks to Buy According to Hedge Funds? (Insider Monkey) +5.75%
Nov-29-24 05:58PM	Fluent, Inc. Announces $5.75 Million Registered Direct Offering and $2.75 Million Concurrent Private Offering (GlobeNewswire)
Nov-19-24 04:00PM	Fluent, Inc. Files New Investor Presentation and Makes Available on Company Website (GlobeNewswire) -5.32%
Nov-15-24 01:04PM	Q3 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -6.62%
02:15AM	Fluent Inc (FLNT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ... (GuruFocus.com)
Nov-14-24 05:12PM	Fluent: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces Third Quarter 2024 Financial Results; Strategic Pivot Accelerates with Growth of Commerce Media Solutions (GlobeNewswire)
Nov-13-24 02:30PM	Fluent, Inc. to Announce 2024 Third Quarter Financial Results on November 14, 2024 (GlobeNewswire) -5.33%
Sep-10-24 10:00AM	Ryan Perfit Appointed Chief Financial Officer of Fluent, Inc. (GlobeNewswire)
Sep-06-24 08:30AM	Fluent, Inc. to Participate in the 17th Annual Barrington Research Virtual Fall Investment Conference (GlobeNewswire)
Aug-22-24 09:40AM	Are Investors Undervaluing Fluent (FLNT) Right Now? (Zacks)
Aug-20-24 08:11AM	Q2 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -9.67%
Aug-19-24 05:10PM	Fluent (FLNT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:00PM	Fluent Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-15-24 10:00AM	Fluent, Inc. to Announce 2024 Second Quarter Financial Results on August 19, 2024 (GlobeNewswire)
Jul-12-24 08:30AM	Fluent, Inc. Announces Strategic Partnership with US Retailer, Hy-Vee, and Its Retail Media Network, RedMedia, to Enhance Customer Experience (GlobeNewswire)
Jun-28-24 08:30AM	Fluent, Inc. Announces Inclusion in Russell Microcap Index (GlobeNewswire) +7.76%
May-28-24 09:40AM	Is Fluent (FLNT) Stock Undervalued Right Now? (Zacks)
May-16-24 11:39AM	Q1 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -13.10%
08:16AM	Fluent, Inc. (NASDAQ:FLNT) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
03:07AM	Fluent Inc (FLNT) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts Amid Revenue ... (GuruFocus.com)
May-15-24 08:52PM	FLNT Stock Earnings: Fluent Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:45PM	Fluent: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 01:19PM	Fluent, Inc. to Announce 2024 First Quarter Financial Results on May 15, 2024 (GlobeNewswire)
May-02-24 07:00AM	SLR Credit Solutions Agents Senior Credit Facility for Fluent, Inc. (Business Wire)
Apr-10-24 08:00AM	Fluent Announces Reverse Stock Split (GlobeNewswire)
Apr-03-24 09:00AM	Influencer Media Group Infuse Follows Up on Stellar 2023 Growth with New Partnership, Podcast Launch, and Influencer Events (GlobeNewswire)
06:44AM	Q4 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-02-24 05:32PM	Fluent Announces Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Apr-01-24 10:48PM	Fluent, Inc. to Announce Fourth Quarter and Full-Year 2023 Financial Results on April 2, 2024 (GlobeNewswire)
Mar-21-24 09:00AM	Fluent Partners with Fyllo Semasio to Expand Audience Solutions with Contextual Offering (GlobeNewswire)
Feb-29-24 02:25PM	Fluent (FLNT) Reports Break-Even Earnings for Q4 (Zacks) +9.44%
12:22PM	Fluent Announces Expected Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 09:00AM	New Fluent Survey of Retailers and Brands Measures Commerce Media Strategies and Challenges (GlobeNewswire) -5.51%
Jan-25-24 08:30AM	Fluent Secures Top Spot as the #1 Digital Agency in Ad Age's 2024 Best Places to Work List (GlobeNewswire)
Nov-15-23 09:55AM	Q3 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -16.50%
Nov-14-23 05:11PM	UPDATE - Fluent Announces Third Quarter 2023 Financial Results (GlobeNewswire) +6.64%
04:54PM	Fluent: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 03:00PM	Fluent, Inc. to Announce Third Quarter Financial Results on November 14, 2023 (GlobeNewswire) +5.55%
Aug-22-23 08:30AM	Fluent, Inc. Launches Infuse Influencer Platform to Unlock New Customer Acquisition Opportunities for Advertisers (GlobeNewswire)
Aug-15-23 12:04PM	Fluent, Inc. (NASDAQ:FLNT) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:05AM	Q2 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:30PM	Fluent Announces Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 09:09PM	7 Stocks That Could Triple Your Money by 2024 (InvestorPlace)
Aug-08-23 08:30AM	Fluent Launches Post-Transaction Ecommerce Advertising Solution (GlobeNewswire)
Aug-02-23 08:30AM	AdParlor Introduces CreatorFuel: A Full-Funnel Influencer Marketing Solution (GlobeNewswire)
Aug-01-23 03:30PM	Fluent, Inc. to Announce Second Quarter Financial Results on August 14, 2023 (GlobeNewswire)
Jul-27-23 08:30AM	Fluent, Inc.'s 2023 Mobile Gaming Survey Reveals Generational Insights into Gamers' Behavior and Preferences (GlobeNewswire)
Jul-10-23 10:14AM	Several Insiders Invested In Fluent Flagging Positive News (Simply Wall St.)
Jun-13-23 08:42AM	Investors in Fluent (NASDAQ:FLNT) have unfortunately lost 77% over the last five years (Simply Wall St.)
May-17-23 06:15AM	Investors Will Want Fluent's (NASDAQ:FLNT) Growth In ROCE To Persist (Simply Wall St.)
May-16-23 08:01AM	Q1 2023 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -20.19%
May-15-23 04:15PM	Fluent Announces First Quarter 2023 Financial Results (GlobeNewswire)

Fluent, Inc. engages in the provision of digital marketing services. It operates through the Fluent and All Other segments. The Fluent segment includes delivering data and performance-based marketing executions. The All Other segment represents the operation results of AdParlor, LLC, a digital advertising solution for social media buying. The company was founded by Ryan Schulke and Matthew Conlin in 2001 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Perfit Ryan MacNab	Chief Financial Officer	Sep 09 '25	Sale	2.05	3,662	7,507	66,934	Sep 15 04:20 PM
Conlin Matthew	Chief Customer Officer	Jun 24 '25	Option Exercise	0.00	862,743	431	2,463,861	Jul 03 09:33 PM
Conlin Matthew	Chief Customer Officer	Jun 24 '25	Option Exercise	0.00	316,375	158	441,391	Jul 03 09:33 PM
Schulke Ryan	Chief Strategy Officer	Jun 24 '25	Option Exercise	0.00	811,133	406	3,752,228	Jul 03 08:57 PM
Schulke Ryan	Chief Strategy Officer	Jun 24 '25	Option Exercise	0.00	229,990	115	333,017	Jul 03 08:57 PM
Patrick Donald Huntley	Chief Executive Officer	Jun 24 '25	Option Exercise	0.00	30,795	15	331,681	Jul 03 08:25 PM
Patrick Donald Huntley	Chief Executive Officer	Jun 10 '25	Sale	1.81	28,172	51,101	300,891	Jun 20 06:20 PM
FROST PHILLIP MD ET AL	10% Owner	Mar 20 '25	Option Exercise	0.00	459,981	230	4,838,037	Mar 21 07:33 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Dec 05 '24	Buy	2.69	14,337	38,554	3,056,403	Dec 06 04:30 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Dec 04 '24	Buy	2.74	5,045	13,826	3,042,066	Dec 06 04:30 PM

Open in Screener

COCP

Cocrystal Pharma Inc

Oct 31 • 04:00PM ET

1.09

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

COCP Cocrystal Pharma Inc daily Stock Chart

Peers: MRNA BNTX GILD REGN PFE JNJ VRTX AZN NVAX SNY

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	36.50%	Shs Outstand	10.17M	Perf Week	-7.63%
Market Cap	14.21M	Forward P/E	-	EPS next Y	-0.86	Insider Trans	0.00%	Shs Float	8.28M	Perf Month	-10.66%
Enterprise Value	11.03M	PEG	-	EPS next Q	-0.21	Inst Own	5.27%	Short Float	2.99%	Perf Quarter	-43.81%
Income	-12.56M	P/S	-	EPS this Y	53.20%	Inst Trans	-3.32%	Short Ratio	0.16	Perf Half Y	-31.87%
Sales	0.00M	P/B	2.08	EPS next Y	-7.45%	ROA	-83.52%	Short Interest	0.25M	Perf YTD	-46.04%
Book/sh	0.52	P/C	2.94	EPS next 5Y	14.11%	ROE	-110.56%	52W High	3.26 -66.56%	Perf Year	-42.25%
Cash/sh	0.37	P/FCF	-	EPS past 3/5Y	-120.49% -2.62%	ROIC	-188.21%	52W Low	1.01 7.92%	Perf 3Y	-49.77%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.87% 6.75%	Perf 5Y	-89.53%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	29.97%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-99.61%
Dividend Ex-Date	-	Quick Ratio	3.69	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.70	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.69	EPS Q/Q	61.54%	SMA20	-2.77%	Beta	2.24	Target Price	9.00
Payout	-	Debt/Eq	0.31	Sales Q/Q	-	SMA50	-15.06%	Rel Volume	0.03	Prev Close	1.09
Employees	11	LT Debt/Eq	0.25	Earnings	Aug 14 BMO	SMA200	-29.47%	Avg Volume	1.53M	Price	1.09
IPO	Apr 01, 2008	Option/Short	No / Yes	EPS/Sales Surpr.	13.04% -	Trades		Volume	47,727	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-20	Initiated	H.C. Wainwright	Buy	$5

Oct-30-25 08:00AM	Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-27-25 08:00AM	Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program (GlobeNewswire)
Oct-02-25 08:00AM	Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference (GlobeNewswire)
Sep-15-25 04:30PM	Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -9.49% -7.69%
Sep-12-25 09:43AM	Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +9.72%
08:00AM	Loading…
08:00AM	Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference (GlobeNewswire)
Sep-08-25 08:00AM	Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment (GlobeNewswire)
Sep-03-25 08:00AM	Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-14-25 08:00AM	Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Aug-05-25 08:00AM	Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference (GlobeNewswire) -14.95%
Jul-10-25 08:00AM	Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference (GlobeNewswire)
Jun-05-25 08:00AM	Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference (GlobeNewswire)
May-29-25 08:00AM	Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain (GlobeNewswire) +8.74%
May-28-25 08:00AM	Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference (GlobeNewswire)
May-15-25 08:00AM	Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
08:00AM	Loading…
Apr-24-25 08:00AM	Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants (GlobeNewswire)
Apr-16-25 08:00AM	Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference (GlobeNewswire)
Mar-31-25 08:00AM	Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-06-25 08:00AM	Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections (GlobeNewswire) +6.50%
Jan-02-25 06:34AM	Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial (Clinical Trials Arena) +14.85%
Dec-31-24 02:03PM	Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement (GuruFocus.com) -37.85%
08:00AM	Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 (GlobeNewswire)
Nov-13-24 08:00AM	Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Oct-31-24 08:00AM	Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins (GlobeNewswire)
Sep-26-24 08:00AM	Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts (GlobeNewswire)
Aug-19-24 04:05PM	Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences (GlobeNewswire) +15.38% -9.05%
Aug-15-24 03:00PM	CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event (ACCESSWIRE)
08:00AM	Loading…
Aug-14-24 08:00AM	Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire) -10.53%
Jul-18-24 08:00AM	Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor (GlobeNewswire)
Jun-20-24 08:00AM	New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows (GlobeNewswire)
Jun-07-24 09:55AM	Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy? (Zacks)
May-13-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
May-01-24 08:00AM	Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza (GlobeNewswire)
Mar-28-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023 (InvestorPlace) -6.67%
08:00AM	Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-19-24 08:00AM	Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A (GlobeNewswire)
Mar-05-24 08:30AM	Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
Jan-04-24 08:00AM	Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates (GlobeNewswire)
Dec-06-23 08:00AM	Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-29-23 08:00AM	Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Nov-27-23 08:00AM	Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 (GlobeNewswire) +17.12%
Nov-13-23 08:00AM	Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Nov-09-23 08:00AM	Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Oct-31-23 08:00AM	Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 (GlobeNewswire) +5.25%
Oct-02-23 12:14PM	COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial. (Zacks)
Sep-28-23 08:00AM	Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus (GlobeNewswire)
Sep-05-23 08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -8.38%
Aug-16-23 09:11AM	COCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline. (Zacks)
Aug-14-23 08:00AM	Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Aug-08-23 08:00AM	Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead (GlobeNewswire) +7.39%
May-31-23 08:00AM	Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988 (GlobeNewswire)
May-17-23 09:26AM	COCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline. (Zacks Small Cap Research) -5.88%
May-15-23 08:00AM	Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire) -5.28%
May-04-23 04:05PM	Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-24-23 08:00AM	Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors (GlobeNewswire) +6.05%
Apr-18-23 08:00AM	Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-10-23 08:30AM	Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +12.95%
Mar-31-23 10:05AM	COCP: UPDATE: Cocrystal Pharma announces full year 2022 financial results and provides drug program updates. (Zacks Small Cap Research) +5.85%
Mar-29-23 08:00AM	Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Mar-22-23 01:03PM	COCP: UPDATE: Cocrystal Pharma announced several program updates and investor events. (Zacks Small Cap Research)
08:00AM	Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023 (GlobeNewswire)
Jan-26-23 08:00AM	Cocrystal Pharma Announces Participation in Virtual Investor Events (GlobeNewswire) -6.62%
Jan-23-23 09:00AM	Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast (Newsfile)
Dec-19-22 08:00AM	Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire) -11.39%
Dec-01-22 04:05PM	Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022 (GlobeNewswire)
Nov-17-22 01:38PM	Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A (Benzinga)
08:00AM	Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-15-22 11:19AM	COCP: UPDATE: Cocrystal Pharma releases 2022 3rd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research)
Nov-14-22 08:00AM	Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Nov-02-22 08:00AM	Cocrystal Pharma to Participate in Two Investor Conferences in November (GlobeNewswire) +13.41%
Nov-01-22 04:05PM	Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza (GlobeNewswire)
Oct-26-22 08:00AM	Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharmas Oral Antiviral Candidate CC-42344 (GlobeNewswire)
Oct-19-22 08:00AM	Cocrystal Pharma to Present at the LD Micro Main Event XV (GlobeNewswire)
Oct-13-22 08:00AM	Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022 (GlobeNewswire)
Oct-11-22 11:51AM	Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate (Benzinga) -9.02%
08:00AM	Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 (GlobeNewswire)
Oct-05-22 08:00AM	Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference (GlobeNewswire)
Oct-03-22 04:05PM	Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split (GlobeNewswire) -13.65%
Sep-06-22 10:05AM	Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth (Simply Wall St.)
08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-19-22 08:10AM	COCP: UPDATE: Cocrystal Pharma releases 2022 2nd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research) -6.42%
Aug-15-22 08:00AM	Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Aug-08-22 08:00AM	Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344 (GlobeNewswire)
Aug-03-22 09:00AM	Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast (Newsfile)
Jul-14-22 08:00AM	Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing (GlobeNewswire)
Jun-01-22 08:00AM	Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors (GlobeNewswire)
May-18-22 08:00AM	Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-12-22 08:12AM	COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs (Zacks Small Cap Research)
May-11-22 08:00AM	Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones (GlobeNewswire) -5.02%
Apr-21-22 08:00AM	Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors (GlobeNewswire)
Apr-19-22 08:00AM	Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference (GlobeNewswire)
Apr-14-22 08:00AM	Cocrystal Pharma to Present at the Noble Capital Markets NobleCon18 Conference (GlobeNewswire)
Apr-12-22 11:01AM	Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial (Benzinga)
08:00AM	Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral (GlobeNewswire)
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts (Insider Monkey)
Mar-30-22 02:57PM	We're Hopeful That Cocrystal Pharma (NASDAQ:COCP) Will Use Its Cash Wisely (Simply Wall St.)

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create first- and best-in-class antiviral drugs. The company was founded in 2008 and is headquartered in Bothell, WA.

OPK

Opko Health Inc

BCDA

BioCardia Inc

FLNT

Fluent Inc

COCP

Cocrystal Pharma Inc

Upgrade your FINVIZ experience